The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study Meeting Abstract

  

Authors:	Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; Wong, S.; Yang, Y. C.; Jiang, J. J.; Bitman, B.; Singh, M.; Gustafson, W. C.; Rosen, N.; Schram, A. M.
Abstract Title:	The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680300991
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.3098
Notes:	Meeting Abstract: 3098 -- This meeting was also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201316